Overview - Tianjin Lifeng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the listing application of Adenine Phosphate raw material [2] Product Information - The product, Adenine Phosphate, is a chemical raw material with a molecular weight of 233.12 and a molecular formula of C5H5N5·H3PO4 [2] - It is used clinically to prevent and treat leukopenia caused by various reasons, particularly in cases related to chemotherapy, radiation therapy, and benzene poisoning [2] Impact on the Company - The approval of this product's listing application is expected to enhance the company's market competitiveness by creating industrial synergy with its formulation products [3]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of hydrochloride erlotinib, a targeted drug for treating non-small cell lung cancer [1] Group 1: Product Approval - The approval pertains to hydrochloride erlotinib, classified as an EGFR tyrosine kinase inhibitor [1] - This drug is primarily used for treating locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene [1] - It can also be used for patients with advanced non-small cell lung cancer who have failed previous chemotherapy [1]

Core Viewpoint - The approval of the raw materials for Palbociclib and Dapagliflozin indicates compliance with national drug registration requirements, enhancing the company's product line and competitiveness, and promoting sustainable and healthy development [2]. Group 1: Product Approvals - The company received the approval notice for the raw materials of Palbociclib and Dapagliflozin from the National Medical Products Administration [1]. - Palbociclib is a CDK4/6 inhibitor used for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1]. - Dapagliflozin is an SGLT-2 inhibitor used for improving blood sugar control and reducing cardiovascular risks in adults with heart failure [1]. Group 2: Strategic Implications - The approval of these raw materials will enrich the company's product line, enhancing its competitiveness in the pharmaceutical market [2]. - The introduction of these drugs is expected to contribute to the company's continuous, stable, and healthy development [2].

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing of two active pharmaceutical ingredients: Palbociclib and Dapagliflozin [1] Group 1: Product Approvals - Palbociclib is a CDK4/6 inhibitor indicated for the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer [1] - Dapagliflozin is a novel oral hypoglycemic agent classified as an SGLT-2 inhibitor, which can be used as monotherapy or in combination therapy to improve blood glucose control based on diet and exercise [1]

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. has received the approval notice for the listing application of the chemical raw material drug Bupivacaine from the National Medical Products Administration, which will enhance the company's product line and core competitiveness [1][4]. Group 1: Approval Information - The chemical raw material drug approved is Bupivacaine, with registration number Y20230001273 [1]. - The application for the drug was submitted in December 2023, accepted in January 2024, and recently approved [2]. Group 2: Product Application - Bupivacaine is primarily used in clinical settings for local anesthesia and postoperative analgesia [3]. Group 3: Impact on the Company - The approval of Bupivacaine will enrich the company's product line and enhance its core competitiveness [4].

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the market launch of Eicosapentaenoic Acid Ethyl Ester as a chemical raw material drug [1] Group 1 - The application for the domestic production of Eicosapentaenoic Acid Ethyl Ester was submitted in June 2023 and was accepted [1] - The approval notification was granted in May 2025, with a review conclusion of registration approval [1]